|Bid||5.00 x 3200|
|Ask||5.08 x 47300|
|Day's Range||4.97 - 5.19|
|52 Week Range||0.97 - 7.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
ArQule Inc’s (NASDAQ:ARQL): ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The US$548.4m market-cap company’s loss lessensRead More...
ArQule, Inc. (ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to miransertib (ARQ 092) for the treatment of PIK3CA-Related Overgrowth Spectrum (PROS), a group of related, ultra-rare genetic disorders characterized by excessive tissue growth in various parts of the body. The FDA’s Fast Track program aims to expedite the development and review of drugs which treat serious or life-threatening conditions and have demonstrated the potential to address unmet clinical needs. Miransertib has already been granted Rare Pediatric Disease Designation by the FDA and Orphan Designation by the FDA and European Medicines Agency in the rare overgrowth disease, Proteus syndrome.
ArQule, Inc. today announced that Paolo Pucci, CEO, and Dr. Brian Schwartz, CMO and Head of Research and Development, will participate in investor meetings and scientific panel discussions at the B.
ArQule, Inc. today announced that Paolo Pucci, CEO, Peter Lawrence, President and COO, Brian Schwartz, CMO and Head of R&D and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in Citi’s 13th Annual Biotech Conference on September 6, 2018, at the Four Seasons Hotel in Boston, MA.
ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Strategy, Communication and Finance, will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PagSeguro ...
ArQule, Inc. (ARQL), today announced the publication of preclinical study data for ARQ 531, the Company’s rationally-designed, reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). The studies, published in Cancer Discovery, were conducted in collaboration with researchers at The Ohio State University.
ArQule (ARQL) delivered earnings and revenue surprises of 150.00% and 78.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / ArQule, Inc. (NASDAQ: ARQL ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 9:00 AM Eastern Time. To listen ...
The Burlington, Massachusetts-based company said it had net income of 5 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
ArQule, Inc. (ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.
ArQule, Inc. (ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,650,000 shares at the public offering price of $5.50 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by ArQule to 12,650,000 shares and increased the gross proceeds raised in the offering, before deducting underwriting discounts and commissions and estimated expenses of the offering payable by ArQule, to approximately $70 million. Needham & Company, LLC acted as lead co-manager, and Roth Capital Partners, B. Riley FBR and JonesTrading Institutional Services LLC acted as co-managers for the offering.
On Wednesday, July 11, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), ArQule Inc. (NASDAQ: ARQL), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Atara Biotherapeutics Inc. (NASDAQ: ATRA).
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 10) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics ...
ArQule’s (ARQL) product candidates include ARQ 531, which is in Phase 1 for B-cell malignancies refractory to other therapeutic options. Its product candidates also include ARQ 092, which is in a Phase 1 Part 2 study for rare overgrowth diseases and Phase 1 for Proteus syndrome, which is a rare disease.
ArQule, Inc. (ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1.65 million shares of its common stock. The gross proceeds to ArQule from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be $60.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by ArQule.
ArQule, Inc. (ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ArQule’s (ARQL) research pipeline is focused on molecular targets and biological processes that have a role in the development of human cancers and rare diseases. With the exception of derazantinib, all the compounds in its pipeline are owned by ArQule. In February, ArQule entered into a derazantinib license agreement with Sinovant Sciences, which is a subsidiary of Roivant Sciences.
ArQule’s first-quarter revenues included $3.0 million received from Roivant as an upfront payment for a February agreement. ArQule is expected to generate revenues of $16.97 million in fiscal 2018, $5.84 million in fiscal 2019, and $12.76 million in fiscal 2020. In the first quarter, ArQule (ARQL) incurred research and development expenses of $5.81 million compared with $5.19 million in the first quarter of 2017.